MT
MTST.US MetaStat Inc
- Market cap
- USD 4.11K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Feb 2023.
Is MTST.US undervalued?
Graham numberThe Graham number of MetaStat Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MetaStat Inc fundamental analysis
No fundamental analysis for MetaStat Inc yet.
MetaStat Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MetaStat Inc
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK …
Full company profileMetaStat Inc financial statements
MetaStat Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 23.3K | - | - | - | - |
| Gross Profit | - | 0.00 | 0.00 | 0.00 | -1.01M | 23.3K | - | - | - | - |
| Operating Income | 2.52M | 4.35M | 4.79M | 4.78M | 3.35M | -3.55M | - | - | - | - |
| EBITDA | -4.36M | -4.91M | -4.24M | -1.78M | -2.97M | -3.46M | - | - | - | - |
| Net Income | -2.52M | -5.37M | -8.00M | -4.65M | -2.94M | -3.18M | - | - | - | - |
| EPS | -1.81 | -3.80 | -4.81 | -2.56 | -0.99 | -0.59 | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 1.02M | 791K | 1.10M | 1.06M | 1.26M | 730K | - | - | - | - |
| Total Liabilities | 887K | 2.87M | 859K | 2.83M | 4.06M | 2.28M | - | - | - | - |
| Shareholders' Equity | 136K | -2.08M | 243K | -1.77M | -2.80M | -1.55M | - | - | - | - |
| Cash & Short-term Investments | 969K | 483K | 258K | 364K | 783K | 317K | - | - | - | - |
| Total Debt | 717K | 2.48M | 270K | 1.53M | 989K | 1.00M | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.40M | -2.20M | -3.58M | -3.14M | -2.31M | -2.74M | - | - | - | - |
| Capital Expenditure | 45.2K | 173K | 65.6K | 152K | 13.4K | 30.1K | - | - | - | - |
| Free Cash Flow | -2.44M | -2.37M | -3.65M | -3.29M | -2.33M | -2.77M | - | - | - | - |
| Ratios | ||||||||||
| ROE | -1,858.7% | - | -3,295.1% | - | - | - | - | - | - | - |
| ROA | -246.5% | -678.6% | -725.5% | -438.0% | -233.1% | -436.0% | - | - | - | - |
| Net Profit Margin | - | - | - | - | - | -13,652.5% | - | - | - | - |
| Debt to Equity | 5.29x | - | 1.11x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MetaStat Inc dividends
MetaStat Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:15 on Oct 8, 2015.
Who owns MetaStat Inc
- Insiders 1.57%
- Institutions 0.00%
- Public & others 98.43%
- Shares outstanding 5.88M
- Free float 5.79M
MetaStat Inc company profile
- Company name
- MetaStat Inc
- Ticker
- MTST.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 6
- Fiscal year end
- February
- Address
- 27 Drydock Avenue, Boston, MA, United States, 02210
- Phone
- 617-531-6500
- Website
- metastat.com
About MetaStat Inc
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.
MetaStat Inc management
1- Mr. Frederick E. Pierce IIVice President of Investor Relations · born 1962